title: [Immunophenotyping of 106 adult patients with acute leukemia by flow cytometry].
abstract: OBJECTIVE
  To study the immunophenotyping of adult patients with acute leukemia and its association with the prognosis.
  
  
  METHODS
  Immunophenotyping was performed in 106 adult patients with acute leukemia by three-color flow cytometry analysis using CD34/SSC gating.
  
  
  RESULTS
  The antigens expressed in 71 patients with acute myeloid leukemia (AML) were mainly CD13, CD33, HLA-DR, CD34 and CD117. Lymphoid antigen expression was identified in 23.9% adult AML patients and CD56 antigen expression in 15.5% of the AML patients. In 29 patients with acute lymphoblastic leukemia (ALL), the expressed antigens were mainly HLA-DR, CD10, CD19, CD34 and CD7, and 34.5% of these patients were found to be positive for myeloid antigen expression. Complete remission (CR) rate in AML patients with lymphoid antigen expression after chemotherapy was lower than that in AML patients without lymphoid antigen expression (52.9% vs 77.8%, P<0.05), and no significant impact was noted of myeloid antigen expression in ALL on the CR of the patients (70.0% vs 94.7%, P>0.05). The CR rate in AML with CD56 antigen expression was lower than that in AML without CD56 expression (36.4% vs 78.3%, P<0.025), and the CR rate in CD34+ AML was lower than that in CD34- AML (56.0% vs 80.4%, P<0.05).
  
  
  CONCLUSIONS
  Gating of CD45/SSC can eliminate the interference of normal cells to render more reliable immunophenotyping results. The expressions of CD56+, CD34+, lymphoid antigen in adult AML patients, who have lower CR rate, often signify poor prognosis.
authors.affiliation: Department of Hematology, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China. XBZJ@fimmu.edu.cn
authors.forename: Bing
authors.initials: B
authors.lastname: Xu
authors.forename: Cheng
authors.initials: C
authors.lastname: Hu
authors.forename: Xu-dong
authors.initials: XD
authors.lastname: Miao
authors.forename: Yan-hong
authors.initials: YH
authors.lastname: Wu
authors.forename: Zheng-shan
authors.initials: ZS
authors.lastname: Yi
authors.forename: Yi
authors.initials: Y
authors.lastname: Yang
authors.forename: Fan-yi
authors.initials: FY
authors.lastname: Meng
authors.forename: Ru
authors.initials: R
authors.lastname: Feng
authors.forename: Qi-fa
authors.initials: QF
authors.lastname: Liu
authors.forename: Xiao-li
authors.initials: XL
authors.lastname: Liu
authors.forename: Wei-yang
authors.initials: WY
authors.lastname: Zheng
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019002:CD56 Antigen / Q000032:analysis; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000276:immunology*; D017493:Leukocyte Common Antigens / Q000032:analysis; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000276:immunology*; D011379:Prognosis
chemical_list: D019002:CD56 Antigen; D017493:Leukocyte Common Antigens